Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*Nuala J. Meyer, Steven M. Opal, Tiffanie K. Jones et al.|Critical Care Medicine|2017Cited by 98